- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04729543
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer (MC2TCR)
Adoptive Therapy With TCR Gene-engineered T Cells to Treat Patients With MAGE-C2-positive Melanoma and Head and Neck Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this patient study, the investigators target the Cancer Germline Antigen (CGA) MAGE-C2 (MC2), and use T cells with a young phenotype. MC2 is highly expressed in melanoma (MEL) and head-and-neck squamous cell carcinoma (HNSSC), but not in healthy adult tissues. The investigators isolated MC2-specific TCRs from MEL patients who showed clinical responses following vaccination that were accompanied by significant frequencies of anti-MC2 CD8 T cells in blood and tumor without apparent side effects. Following extensive evaluation of in vitro anti-tumor and self-reactivities, the investigators have selected a TCR that recognizes the ALK epitope in the context of HLA-A2 for clinical development. Furthermore, preclinical studies showed that epigenetic pretreatment of tumor cells, but not normal cells, up-regulated MC2 gene expression and resulted in enhanced recognition of MC2 by the selected TCR. In parallel to the above studies, the investigators renewed their GMP protocol to process T cells, using stimulating antibodies and cytokines, to generate T cells with a young phenotype.
In the current phase I/II study, the investigators explore the safety and anti-tumor efficacy of T cells engineered with the selected TCR in patients with MC2-positive MEL and HNSSC. The study contains the following unique elements:
- CGA not targeted before by T cell therapy
- New T cell processing method to generate young T cells
- Pretreatment of patients with epigenetic drugs
- No chemotherapy prior to T cell infusion
Leads:
- Clinical PI: Astrid van der Veldt, MD, PhD
- Clinical logistics: Karlijn de Joode, MD
- T cell production: Monique de Beijer, PhD; and Cor Lamers, PhD
- Coordinator/Preclinical PI: prof. Reno Debets, PhD
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: A.A.M. van der Veldt, MD, PhD
- Phone Number: +31 107041754
- Email: a.vanderveldt@erasmusmc.nl
Study Contact Backup
- Name: R. Debets, PhD, Prof
- Phone Number: +31 107038307
- Email: j.debets@erasmusmc.nl
Study Locations
-
-
-
Rotterdam, Netherlands, 3015GD
- Recruiting
- Erasmus Medical Center
-
Contact:
- A.A.M. van der Veldt, MD, PhD
- Phone Number: +31 107041754
- Email: a.vanderveldt@erasmusmc.nl
-
Contact:
- R. Debets, PhD, Prof.
- Phone Number: +31 107038307
- Email: j.debets@erasmusmc.nl
-
Sub-Investigator:
- Karlijn de Joode, MD
-
Sub-Investigator:
- Monique de Beijer, PhD
-
Sub-Investigator:
- Cor Lamers, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent;
- Age ≥ 18 years;
One of the following three malignancies:
- Previously treated for unresectable or metastatic cutaneous or mucosal melanoma for whom no standard treatment is available (anymore);
- Metastatic uveal melanoma, progressing after standard of care therapy, if available;
- R/M HSNCC for whom no standard treatment is available anymore;
- Patients must be HLA-A2*0201 positive;
- Primary tumor and/or metastasis (archival or fresh biopsy) is positive for MC2 (>5% of tumor cells) according to immunohistochemistry;
- Measurable disease according to RECIST v1.1;
- At least one lesion, suitable for sequential mandatory tumor biopsies;
- ECOG performance status of 0 or 1. Life expectancy ≥ 12 weeks;
- Patients with melanoma must have had objective evidence of disease progression while on or after standard systemic therapy. The last dose of prior therapy (e.g. anti- PD-1, chemotherapy) must have been received more than 4 weeks prior to the start of study treatment. For melanoma patients who are treated with BRAF- and MEK inhibitors, an interval of 2 weeks between discontinuation of BRAF- and MEK inhibition and start of study treatment is sufficient;
- Patients with R/M HNSCC must have had objective evidence of disease progression and are ineligible for or unwilling to get platinum-based chemotherapy or for whom no standard treatment is available;
- Patients of both genders must be willing to practice a highly effective method of birth control during treatment and for four months after receiving the preparative regimen;
- Patients must meet the following laboratory values at the screening visit in the absence of growth factors and/or transfusion support:
Hematology:
- absolute neutrophil count greater than 1.5x10^9/L;
- platelet count greater than 75x10^9/L;
- hemoglobin greater than 5 mmol/L or 8.0 in g/dl;
Chemistry:
- serum ALAT/ASAT less than 3 times the upper limit of normal (ULN), unless patients have liver metastasis (<5 times ULN);
- serum creatinine < 1.5 ULN;
- total bilirubin ≤ 20 micromol/L, except in patients with Gilbert's Syndrome who must have a total bilirubin ≤ 50 micromol/L;
Serology:
- seronegative for HIV antibody;
- seronegative for hepatitis B antigen, and hepatitis C antibody;
- seronegative for lues.
Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from participation of this study:
- presence of symptomatic brain metastasis. Note: subjects with symptomatic brain lesions who have been definitively treated with stereotactic radiation therapy, surgery, or gamma knife therapy are eligible;
- Presence of active brain metastasis defined as new or progressive brain metastasis at the time of study entry. Note: subjects with treated or stable brain metastasis are eligible;
- Presence of leptomeningeal metastasis;
- Presence of malignant pleural effusion or ascites;
- Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any other immunosuppressive therapy within 7 days prior to leukapheresis or 72 hours prior to infusion of the MC2 TCR T cells. Note: local steroids such as topical, inhaled, nasal and ophthalmic steroids are allowed;
- Active, known or suspected autoimmune disease or a documented history of autoimmune disease. Note: subjects with vitiligo, controlled type 1 diabetes mellitus on stable insulin dose, residual autoimmune-related hypothyroidism only requiring hormone replacement or psoriasis not requiring systemic treatment are permitted;
- Any active systemic infections, coagulation disorders or other active major medical illnesses, such as active autoimmune diseases requiring anti-TNF treatment;
- History of myocardial infarction, cardial angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 6 months of enrollment;
- AEs of previous treatment. Toxicities associated with prior systemic and non- systemic treatment must have recovered to a grade 1 or less. Patients may have undergone minor surgical procedures or palliative radiotherapy (for non-target lesions) within the past 4 weeks, as long as all toxicities have recovered to grade 1 or less;
- Women who are pregnant or breastfeeding. A negative pregnancy test before inclusion in the trial is required for all women of child bearing age;
- Use of any live vaccines against infectious diseases within the last 3 months;
- Active infection requiring systemic antibiotic therapy at start of study treatment;
- Prior allogenic bone marrow or solid organ transplant;
- History of known hypersensitivity to any of the investigational drugs used in this study;
- Malignant disease, other than being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to start of study treatment, completely resected basal cell and squamous cell skin cancers and any completely resected carcinoma in situ.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adoptive therapy with autologous MC2 TCR T cells
|
Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of MC2 TCR T cells
Time Frame: 1 year
|
MTD is determined using an accelerated titration phase with T cell doses as described in treatment arm; AEs are recorded according to CTCAE 5.0
|
1 year
|
Objective anti-tumor responses of MC2 TCR T cells
Time Frame: 2 years
|
Anti-tumor responses are recorded according to RECIST v1.1 using the MTD from outcome 1
|
2 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Lamers CH, van Steenbergen-Langeveld S, van Brakel M, Groot-van Ruijven CM, van Elzakker PM, van Krimpen B, Sleijfer S, Debets R. T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness. Hum Gene Ther Methods. 2014 Dec;25(6):345-57. doi: 10.1089/hgtb.2014.051.
- Kunert A, van Brakel M, van Steenbergen-Langeveld S, da Silva M, Coulie PG, Lamers C, Sleijfer S, Debets R. MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses. J Immunol. 2016 Sep 15;197(6):2541-52. doi: 10.4049/jimmunol.1502024. Epub 2016 Aug 3.
- Kunert A, Obenaus M, Lamers CHJ, Blankenstein T, Debets R. T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk. Clin Cancer Res. 2017 Oct 15;23(20):6012-6020. doi: 10.1158/1078-0432.CCR-17-1012. Epub 2017 Jun 23.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Head and Neck Neoplasms
- Melanoma
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Valproic Acid
- Azacitidine
- Interleukin-2
Other Study ID Numbers
- NL69011.000.19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
Clinical Trials on Adoptive therapy with autologous MC2 TCR T cells
-
T-knife GmbHTerminatedAdvanced Solid TumorsGermany, Belgium, Spain, Netherlands, United Kingdom
-
Christian HinrichsNational Cancer Institute (NCI)Not yet recruitingCervical Cancer | HPV-Related Malignancy | Vulvar Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Associated Cervical Carcinoma | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditionsUnited States
-
Shanghai Pudong HospitalDuke UniversityRecruitingMetastatic Cancer | Advanced CancerChina
-
Guangzhou 8th People's HospitalSun Yat-sen UniversityCompleted
-
Cell Medica LtdUniversity College, London; Cell Therapy CatapultCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)United Kingdom, Germany, Belgium
-
Verismo TherapeuticsRecruitingOvarian Cancer | Mesothelioma, Malignant | Cholangiocarcinoma RecurrentUnited States
-
University of PennsylvaniaCompletedSubjects With Metastatic Pancreatic Ductal Adenocarcinoma (PDA)United States
-
AdaptimmuneActive, not recruitingMelanoma | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Urinary Bladder Cancer | Synovial Sarcoma | Gastroesophageal Junction | Myxoid Round Cell LiposarcomaUnited States, Canada
-
Zhejiang UniversityYake Biotechnology Ltd.Recruiting